Publikationen, an denen er mitarbeitet UNAX LERTXUNDI ETXEBARRIA (51)

2024

  1. Acetazolamide-induced pulmonary oedema: A disproportionality analysis from the EudraVigilance database

    British Journal of Clinical Pharmacology, Vol. 90, Núm. 7, pp. 1751-1755

  2. Incorporating the One Health philosophy into pharmacovigilanc: Pharmacovigilance

    British Journal of Clinical Pharmacology

  3. Intranasal esketamine and manic symptoms: A disproportionality analysis in EudraVigilance

    European Neuropsychopharmacology

  4. Medication impact on oral health in schizophrenia

    Medicina Oral Patologia Oral y Cirugia Bucal, Vol. 29, Núm. 1, pp. e51-e57

  5. [Translated article] Pharmaceuticals in the environment: A hospital pharmacy perspective

    Farmacia Hospitalaria, Vol. 48, pp. TS13-TS20

2023

  1. Analysis of heat stroke and heat exhaustion cases in EudraVigilance pharmacovigilance database

    European Journal of Clinical Pharmacology, Vol. 79, Núm. 5, pp. 679-685

  2. Comprehensive micropollutant characterization of wastewater during Covid-19 crisis in 2020: Suspect screening and environmental risk prioritization strategy

    Science of the Total Environment, Vol. 873

  3. Knowledge and attitude about drug pollution in pharmacy students: A questionnaire-based cross sectional study

    Currents in Pharmacy Teaching and Learning, Vol. 15, Núm. 5, pp. 461-467

2022

  1. Drugs used during the COVID-19 first wave in Vitoria-Gasteiz (Spain) and their presence in the environment

    Science of the Total Environment, Vol. 820

  2. Farmako antipsikotikoak eta aho-patologia: eragin kaltegarriak jakinarazteko Europako sistemaren bidezko analisia

    Osagaiz: osasun-zientzien aldizkaria, Vol. 6, Núm. 1, pp. 55-66

  3. Subacute thyroiditis and COVID-19 vaccines: a case/non-case study

    Endocrine, Vol. 77, Núm. 3, pp. 480-485

2021

  1. Antipsychotics as environmental pollutants: An underrated threat?

    Science of the Total Environment, Vol. 769

  2. Do cariprazine and brexpiprazole cause impulse control symptoms? A case/non-case study

    European Neuropsychopharmacology, Vol. 50, pp. 107-111

  3. Pharmacotherapeutic management of Parkinson's disease inpatients: How about asking hospital pharmacists?

    European Journal of Hospital Pharmacy, Vol. 28, Núm. e1, pp. E140-E145

  4. Prophylactic laxatives in clozapine-treated patients: A long road ahead

    Revista de Psiquiatria Clinica, Vol. 48, Núm. 1, pp. 66-68

  5. SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database

    Journal of Clinical Pharmacology, Vol. 61, Núm. 2, pp. 187-192

  6. Tramadol-induced hiccups: a case–noncase study in the European pharmacovigilance database

    Therapeutic Advances in Drug Safety, Vol. 12

2019

  1. Antipsychotics and pituitary tumors: An analysis of the European pharmacovigilance database (EudraVigilance)

    International Clinical Psychopharmacology, Vol. 34, Núm. 2, pp. 89-92

  2. Comments on the anticholinergic burden calculator web tool

    Farmacia Hospitalaria

  3. Fractures Related to Tenofovir: A Case/Noncase Study in the European Pharmacovigilance Database

    American journal of therapeutics, Vol. 26, Núm. 5, pp. e589-e592